Analysis of human genetic factors determining anti-HBV immune response to HBV reactivation or HB vaccine after allogeneic hematopoietic cell transplantation

Analysis of human genetic factors determining anti-HBV immune response to HBV reactivation or HB vaccine after allogeneic hematopoietic cell transplantation - HBV response

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053399

Enrollment

Registered

2024-01-20

Start date

2024-03-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancies

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Cases with HBV reactivation in the main study 2) Cases who were assigned to the HB vaccine group in the main study and completed three doses of HB vaccine Cases that meet 1) or 2)

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Analysis of immunological response against post-transplant HBV reactivation and HB vaccine by donor cell genetic factors. Determine whether immune response against HBV reactivation after allogeneic hematopoietic cell transplantation and HB vaccine are affected by HLA type, BTNL2 genetic polymorphism, etc.	—

Countries

Japan

Contacts

Public ContactMasahiro Onozawa

Hokkaido University Hospital Department of Hematology

onozawa@med.hokudai.ac.jp011-706-7214

Outcome results